Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge
The results come amid investor anxiety over the thousands of lawsuits claiming that J&J’s talc-based baby powder and other products caused cancer.
More Stories
GM expects 2025 earnings to be similar to this year’s despite industry headwinds
The Detroit automaker's targeted adjusted earnings before interest and taxes this year is between $13 billion and $15 billion, or...
PepsiCo trims revenue outlook as North American snacking, key international markets lag
PepsiCo lowered its full-year outlook for organic revenue but reiterated its forecast for its earnings growth.
Samsung posts disappointing third-quarter profit guidance as it grapples with AI chips
Samsung posts worse-than-expected guidance for third quarter
Rivian shares fall after EV maker slashes production forecast, misses Q3 delivery expectations
Rivian produced 13,157 vehicles at its manufacturing facility in Normal, Illinois and delivered 10,018 vehicles during the same period.
Modelo brewer Constellation falls despite an earnings beat. Here’s why we’re not concerned
Constellation Brands on Thursday delivered a solid earnings report and set the stage for an anchor to be raised in...
Levi Strauss trims guidance as it weighs sale of Dockers business
Denim-maker Levi Strauss is looking to sell its Dockers brand as the khaki maker drags down the company's overall performance.